<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01164813</url>
  </required_header>
  <id_info>
    <org_study_id>P-604/06-00</org_study_id>
    <nct_id>NCT01164813</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's Under Fasting Conditions</brief_title>
  <official_title>A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's and Relafen® 750 mg Tablets of Glaxosmithkline, in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        -  To Assess the bioequivalence study of Nabumetone 750 mg tablets and Relafen® 750 mg
           tablets in healthy, adult, human subjects under fasting conditions with a washout period
           of 14 days.

        -  To monitor adverse events and ensure the safety of subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open label, two treatment, two period, two sequence, single dose crossover,
      bioequivalence study of nabumetone 750 mg tablets of Dr. Reddy's Laboratories Limited and
      Relafen® 750 mg tablets of Glaxosmithkline research triangle park, in healthy, adult, human
      subjects under fasting conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence study is based on Cmax and AUC parameters</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Nabumetone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relafen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nabumetone</intervention_name>
    <description>Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited</description>
    <arm_group_label>Nabumetone</arm_group_label>
    <other_name>Relafen® 750 mg Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relafen</intervention_name>
    <description>Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.</description>
    <arm_group_label>Relafen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must fulfill all of the following criteria to be considered for inclusion into
        this study:

          -  Subjects who will provide written informed consent

          -  Subjects must be healthy human beings within 18-45 years of age (inclusive) weighing
             at least 50 kg.

          -  Having a Body Mass Index (BMI) between 18.5 and 24.9 (both inclusive), calculated as
             weight in Kg/height in m2

          -  Subjects must be of normal health, as determined by medical history and physical
             examination performed within 21 days prior to the commencement of the study.

          -  Subjects whose screening laboratory values are within normal limits or considered by
             the physician/investigator to be of no clinical significance.

          -  Have normal ECG, X-ray and vital signs.

          -  Availability of the subject for the entire study period and willingness to adhere to
             the protocol requirements as evidenced by written informed consent.

        Exclusion Criteria:

        The subjects will be excluded based on the following criteria:

          -  Subjects incapable of understanding the informed consent.

          -  Subjects who have:

               1. Systolic blood pressure less than 90 mm of Hg and more than 140 mm of Hg

               2. Diastolic blood pressure less than 60 mm of Hg and more than 94 mm of Hg. Minor
                  deviations (2-4 mm of Hg) at check-in may be acceptable at the discretion of the
                  physician/investigator.

               3. Pulse rate below SO/min and above lOO/min.

          -  History of hypersensitivity or idiosyncratic reaction to Nabumetone or any other
             related drugs.

          -  Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal
             function.

          -  Clinically significant illness within 4 weeks before the start of the study.

          -  Consumption of grapefruit for the past ten days prior to the dosing day until the
             completion of the study.

          -  Regular smoker who has a habit of smoking more than nine cigarettes per day and has
             difficulty in abstaining from smoking from 48 hours before dosing and until the
             completion of the study.

          -  Subjects who has taken over the counter or prescribed medications for during the last7
             days from the date of study.

          -  Subjects should not have taken enzyme modifying drugs or any systemic medication
             within the past 30 days prior to start of clinical study

          -  History of any psychiatric illness, which may impair the ability to provide written,
             informed consent.

          -  Subjects with clinically significant abnormal values of laboratory parameters.

          -  Subjects who have participated in any other clinical investigation using experimental
             drug or had bled more than 330 rnL in the past 90 days before the date of start of
             study.

          -  Subjects with positive screen for drugs of abuse and alcohol.

          -  Any subject in whom Nabumetone is contraindicated for medical reasons.

          -  Any subject with recent history of surgery.

          -  A history of difficulty in donating blood.

          -  A positive hepatitis screen including hepatitis B surface antigen, anti HCV and Anti
             HAV antibodies

          -  A positive test result for HIV antibody and/or syphilis

          -  A recent history or presence of asthma (including aspirin induced asthma) or nasa
             polyp.

          -  A recent history of alcoholism &lt; 2 years) or of moderate (180 mL/day) alcohol use,or
             consumption of alcohol within 48 hr prior to receiving Investigational Product.

          -  An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to
             receiving the Investigational Product and throughout the subjects participation in the
             study. In any such case subject selection will be at the discretion of the
             Investigator / Medical expert.

          -  Female subjects who are pregnant or who are able (women with child bearing potential)
             to become pregnant during the study will not be allowed to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Mohan lal Siva Prasad Sayana</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bioserve Clinical Research Private Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bioserve Clinical Research Pvt. Ltd.</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2010</study_first_submitted>
  <study_first_submitted_qc>July 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2010</study_first_posted>
  <last_update_submitted>July 16, 2010</last_update_submitted>
  <last_update_submitted_qc>July 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mr. M.S. Mohan/ Vice President - R &amp; D</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Crossover</keyword>
  <keyword>Nabumetone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nabumetone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

